Very promising depression treatment in the works.
https://www.google.com/amp/s/www.marketwatch.com/amp/story/guid/4033FF7D-3438-4122-9E22-115C851E8B20
“a $2.8 billion clinical-stage biotech stock, rose by 70.6% over the course of the day in response to new results for its late-stage depression drug”
Like a reverse share split…
We’re missing out!
1 Like
Nasdaq write up on Axsome’s jump from a $3 share to a $100 share, including its 115% rise in just 5 business days!
1 Like
Took a dive today (around 7%) after a rival firm has jumped ahead on a rival drug.
Could be a good time to buy?! Exclusivity payout due?
Tie up with Pfizer
1 Like